A randomized, double-blind, placebo-controlled study published in SLEEP by Oxford Academic found that a combination treatment of dronabinol (IHL-42X), a synthetic form of THC, and acetazolamide, significantly reduced the severity of obstructive sleep apnea (OSA).
Conducted by researchers from The University of Western Australia, Monash University, and several Australian hospitals, the study explored the safety and efficacy of this pharmaceutical approach for patients struggling with traditional OSA treatments.
The study enrolled participants with moderate to severe OSA, defined as having an apnea-hypopnea index (AHI) of 15 or more events per hour. Eleven participants underwent one week of nightly IHL-42X at low, medium, and high doses, as well as a placebo, with a one-week washout period between treatments. The primary outcomes measured were changes in AHI, oxygen desaturation index (ODI), daytime sleepiness (Epworth Sleepiness Scale), and mood, while adverse events (AEs) were monitored throughout.
Continue reading